Skip to content

Consistency and comparability test of paper and Chinese electronic version of the Western Ontario and McMaster Universities (WOMAC) scale

Consistency and comparability test of paper and Chinese electronic version of WOMAC scale

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050914
Enrollment
Unknown
Registered
2021-09-08
Start date
2022-10-13
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

group A:First use the paper version of the scale to assess and then use the electronic version of the scale to assess
group B:The electronic version of the scale was used for the assessment first, and then the paper version was used for the assessment.

Sponsors

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria for knee osteoarthritis in the Guidelines for Diagnosis and Treatment of Osteoarthritis (2018 Edition) issued by the Orthopaedic Society of the Chinese Medical Association and the Operation Group; 2. Aged between 40 and 70 years, including 40 and 70 years old, no gender limit; 3. KL classification <= grade 3; 4. Have a mobile phone and be proficient in using the application; 5. Understand Chinese and be able to independently complete the WOMAC questionnaire; 6. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute meniscus injury, peripheral ligament rupture injury, rheumatoid arthritis, rheumatoid arthritis, tumor around the knee joint, tuberculosis, idiopathic osteonecrosis of the knee; 2. Severe cardiovascular, lung, liver, kidney and hematopoietic system diseases, hemophilia and other bleeding diseases, mental illness, pregnancy and lactation; 3. Allergy or intolerance to celecoxib; 4. Received other treatments in the last 2 months that interfered with this study; 5. The investigator determines that the patient is not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
WOMAC score;

Secondary

MeasureTime frame
WOMAC pain subscale score;WOMAC stiffness subscale score;WOMAC physical function subscale score;

Countries

China

Contacts

Public ContactYuan Wei'an
weian_1980@163.com+86 13774269261

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026